BLUEHOLE-NEW-CONSUMPTION
12.5.2022 11:49:09 CEST | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on Vuse overtaking Juul and becoming the U.S vaping market champion again.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005478/en/
Here below is the full article:
According to Nielsen, for the two weeks ended April 9, 2022, Vuse has surpassed Juul and become No.1 in U.S. e-cigarette sales with a market share of 35 percent, driven by the sale of its flagship product Vuse Alto, which represented over 90% of Vuse revenues in the U.S. in 2021. Being back on top in the U.S market has strengthened Vuse's global leadership.
It is another milestone for Vuse to be the U.S top-selling vaping brand again, since Juul overtook it in 2017. Juul, the emerging brand founded in 2015, had already captured a massive 68% share of the US vaping market within 3 years while Vuse's market share had reduced to 10% from 44.2% in 2016.
In order to turn the tide in the competition against Juul, Vuse had started searching for a new manufacturer and atomization technology provider on a global scale, and considered introducing a game-changing product. In 2018, Vuse entered into partnership with FEELM, the flagship atomization tech brand belonging to SMOORE and soon launched Vuse Alto in August.
In contract to Juul, which mounts traditional cotton coil, Vuse Alto provides a revolutionary vaping experience by adopting FEELM ceramic coil, and Vuse also started swinging momentum in its favor. Since 2019, Vuse's US market share has rocketed, with Vuse Alto becoming one of the most popular vaping products worldwide. In 2021, Vuse announced to be No.1 global vaping brand and reached a full year value share of 33.5% in the top five vapor markets (the U.S, Canada, France, Germany and the UK), which account for approximately 75% of total industry vapor revenue (closed-system). In the US market, Vuse’s US value share reached 35.9% in December 2021. It has managed to close 27% value share point gap in just 2 years, with only 0.1% difference with Juul (36%).
Equipped with an industry-leading ceramic coil, Vuse Alto brings a consistently smooth vaping experience and boasts a long-lasting pod with extraordinary leakage-proof performance. Moreover, due to the authentic flavor reproduction of FEELM ceramic coil, Vuse Alto features a full-bodied, rich taste of tobacco and menthol. It becomes an increasingly prominent competitive edge, especially after the U.S FDA banned e-cigarettes with flavors other than tobacco and menthol in February 2020, to address youth vaping epidemic. Meanwhile, Juul has been stuck in youth marketing controversy and faced mounting state lawsuits in the US.
In October 2021, the FDA has issued first marketing granted orders to Vuse (Solo), recognizing the public health benefits of Vuse products, particularly for addicted adult smokers seeking for switchover. Later in April 2022, the FDA has approved NJOY Ace for sale. This latest approved product is also powered by FEELM atomization technology, thereby reaffirming the harm reduction potential of this ceramic coil. Moreover, Vuse Alto shares the same FEELM atomization technology with NJOY Ace.
To read the original article, please visit: https://bluehole.com.cn/news/detail/49834
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005478/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
